"Tenofovir" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone.
| Descriptor ID |
D000068698
|
| MeSH Number(s) |
D02.705.429.906 D03.633.100.759.138.881
|
| Concept/Terms |
Tenofovir- Tenofovir
- 9-(2-Phosphonylmethoxypropyl)adenine
- 9-PMPA (tenofovir)
- 9-(2-Phosphonomethoxypropyl)adenine
|
Below are MeSH descriptors whose meaning is more general than "Tenofovir".
Below are MeSH descriptors whose meaning is more specific than "Tenofovir".
This graph shows the total number of publications written about "Tenofovir" by people in this website by year, and whether "Tenofovir" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 2 | 0 | 2 |
| 2019 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tenofovir" by people in Profiles.
-
Measuring Pre-Exposure Prophylaxis (PrEP) Stigma Among Adolescent Girls and Young Women in Western Kenya: Scale Development, Validation, and Associations with PrEP Adherence. AIDS Patient Care STDS. 2025 Aug; 39(8):323-338.
-
Correlates of Adherence to Oral and Vaginal Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) Participating in the MTN-034/REACH Trial. AIDS Behav. 2024 Sep; 28(9):2990-3000.
-
Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring. PLoS One. 2022; 17(2):e0263664.
-
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. Clin Infect Dis. 2021 10 05; 73(7):1149-1156.
-
HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern. Blood. 2020 09 10; 136(11):1351-1358.
-
Recent HIV Risk Behavior and Partnership Type Predict HIV Pre-Exposure Prophylaxis Adherence in Men Who Have Sex with Men. AIDS Patient Care STDS. 2019 05; 33(5):220-226.
-
Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. AIDS Care. 2019 10; 31(10):1228-1233.
-
Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV. J Acquir Immune Defic Syndr. 2019 01 01; 80(1):e9-e13.
-
Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. J Acquir Immune Defic Syndr. 2017 12 15; 76(5):501-511.
-
Emtricitabine + tenofovir alafenamide for the treatment of HIV. Expert Opin Pharmacother. 2017 Mar; 18(4):427-432.